About the Cardiovascular Molecular and Therapeutics Translational Research Group
Heart Disease

About the Cardiovascular Molecular and Therapeutics Translational Research Group

The Cardiovascular Molecular and Therapeutics Translational Research Group aims to increase understanding of molecular mechanisms of advanced heart failure in order to discover new medicines to treat and improve quality of life for patients with this condition.

Easing the Burden of Heart Failure

The prevalence of heart failure is increasing worldwide, increasing the burden on our hospitals, clinicians, communities and families.

Despite best-available treatment options, patients still have a very poor survival rate.

The research by this group is vital to reduce the burden of patients with heart failure and to provide significantly better outcomes for patients.

Highlights for the research group in 2022

In 2022, the group, which has more than nine members, undertook projects that focused on preventing deadly ventricular arrhythmias in heart failure patients. These included the ‘Antiarrhythmic effect of phenytoin in human failing hearts’ study.

Through this research, the group established that phenytoin is able to effectively prevent arrhythmias in a human ventricular model of arrhythmia, using tissue samples from patients with heart failure.

The research group found that it works effectively to prevent arrhythmias in human heart samples from patients who were not receiving Beta-blockers, also spelled β-blockers, (a kind of medicine that slows down a person’s heart activity) at the time of heart transplantation. This is an important result towards providing an additional medicine in this group of patients.

Using phenytoin as a template medicine, the group then designed and synthesised novel compounds. Remarkably, early attempts found some to be more effective than phenytoin at preventing arrhythmias.

At the same time, the group’s ‘Redesigning and optimizing Beta-blocker treatment for patients with heart failure patients’ project, used pharmacological criteria to re-design Beta-blocker use to enable more patients – including those who were previously unable to tolerate Beta-blocker therapy – to take advantage of treatment.

In 2022, the group was also delighted to appoint Dr Kafa Walweel to the group to provide strategic expertise to develop novel antiarrhythmic medicines for patients with heart failure.

Published: November 14, 2023

Related news & events

Mother-of-four shares story of transplant journey

Patient Stories

Mother-of-four shares story of transplant journey

A Queensland mother who was diagnosed with Idiopathic Pulmonary Fibrosis and Chronic Hypersensitivity Pneumonitis and later received a lung transplant, shares her story here.

Find out more

The journey from the Cycle of Giving to the Tour de Brisbane

The Common Good

The journey from the Cycle of Giving to the Tour de Brisbane

In 2006, Mary and Mal Long started an event called Cycle of Giving to show their gratitude to Mal’s donor family and medical team.

Find out more

Chain Reaction Challenge 2024: Helping Kids visiting The Prince Charles Hospital

The Common Good

Chain Reaction Challenge 2024: Helping Kids visiting The Prince Charles Hospital

In March, dozens of cyclists from Brisbane will take part in a 1000 km cycle in and around Adelaide for the Chain Reaction Challenge 2024.

Find out more

30-year-old heart transplant recipient’s journey to the 2024 Tour de Brisbane

Heart Disease

30-year-old heart transplant recipient’s journey to the 2024 Tour de Brisbane

A Perth father who received a heart transplant three years ago is preparing to take part in the 2024 Tour de Brisbane. Read more about his journey and support his ride here.

Find out more

International Day of Women and Girls in Science 2024

The Common Good

International Day of Women and Girls in Science 2024

This February, we acknowledge International Day of Women and Girls in Science 2024 and some of the remarkable women who are making a difference in STEM.

Find out more

Marfan and Aortopathy Conference Brisbane 2024

The Common Good

Marfan and Aortopathy Conference Brisbane 2024

The Marfan and Aortopathy Conference Brisbane 2024 is on Saturday, April 20, at The Prince Charles Hospital. Click here for more details.

Find out more

What is Marfan Syndrome?

The Common Good

What is Marfan Syndrome?

What is Marfan Syndrome? It affects about 1 in 5000 people across the globe, and for some, it can lead to serious or even life-threatening complications. Learn more here.

Find out more

The Café for The Common Good finds new home at Caboolture Hospital

Social Enterprise

The Café for The Common Good finds new home at Caboolture Hospital

Caboolture Hospital Café: In exciting news, our café has a new home in the hospital’s recently opened Clinical Services Building.

Find out more

Take a walk down Memory Lane at The Prince Charles Hospital

Ageing

Take a walk down Memory Lane at The Prince Charles Hospital

At The Prince Charles Hospital, patients and their families are encouraged to take a trip down the newly completed ‘Memory Lane’. Read about the impactful project here.

Find out more